Symple Surgical

Executive Summary

Symple Surgical Inc. (SSI) is a pre-clinical medical device company developing a novel microwave ablation system for the treatment of resistant hypertension. The company's DirectAblate Catheter delivers controlled microwave energy to achieve depth-specific renal sympathetic denervation, a procedure aimed at reducing overactive nerve signals that contribute to high blood pressure. By minimizing thermal exposure to non-targeted tissues, this approach could offer greater precision and safety compared to existing radiofrequency or ultrasound-based renal denervation technologies. Founded in 2012 and headquartered in San Francisco, CA with an office in Flagstaff, AZ, Symple Surgical has remained in the pre-clinical stage for an extended period, with no disclosed funding rounds or public partnerships, indicating a deliberate but capital-intensive development path. Resistant hypertension affects approximately 10-15% of hypertensive patients, representing a large unmet need for effective interventional therapies. Symple's microwave-based system has the potential to differentiate through improved nerve targeting and reduced collateral damage. However, the company faces significant regulatory and clinical hurdles: it must first complete rigorous pre-clinical studies to demonstrate safety and efficacy, then initiate first-in-human trials. Given its early stage and lack of visible commercial traction, execution risk is high. Nonetheless, the technology's novelty and the size of the addressable market present an attractive opportunity if successful. Key milestones in the near term include finalizing pre-clinical data and securing regulatory clearance for clinical investigation.

Upcoming Catalysts (preview)

• TBDCompletion of pivotal pre-clinical study60% success
• TBDFirst-in-human trial initiation40% success